Related Experiment Video
Updated: May 28, 2026
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
The epothilones: new therapeutic agents for castration-resistant prostate cancer
Tanya B Dorff1, Mitchell E Gross
1Division of Cancer Medicine and Blood Diseases, University of Southern California, Los Angeles, California, USA.
Abstract:
The management of castration-resistant prostate cancer (CRPC) presents a clinical challenge because of limitations in efficacy and durability with currently available therapeutics. The epothilones represent a novel class of anticancer therapy that stabilizes microtubules, causing cell death and tumor regression in preclinical models. The structure of the tubulin-binding site for epothilones is distinct from that of the taxanes. Moreover, preclinical studies suggest nonoverlapping mechanisms of resistance between epothilones and taxanes. In early-phase studies in patients with CRPC, treatment with ixabepilone, a semisynthetic analog of epothilone B, induced objective responses and prostate-specific antigen declines in men previously progressing on docetaxel-based regimens. Clinical activity has been observed in nonrandomized trials for patients with CRPC using ixabepilone in the first- and second-line settings as a single agent and in combination with estramustine. Patupilone and sagopilone were also shown to have promising efficacy in phase II clinical trials of patients with CRPC. All three epothilones appear to be well tolerated, with modest rates of neutropenia and peripheral neuropathy. The lack of crossresistance between epothilones and taxanes may allow sequencing of these agents. Evaluating epothilones in phase III comparative trials would provide much-needed insight into their potential place in the management of patients with CRPC.
Insights
Epothilones, a novel anticancer therapy, show promise in treating castration-resistant prostate cancer (CRPC). These drugs offer potential new options due to distinct mechanisms and lack of cross-resistance with existing treatments.
Area of Science:
- Oncology
- Pharmacology
Background:
- Castration-resistant prostate cancer (CRPC) management is challenging due to limited therapeutic efficacy and durability.
- Epothilones, a novel class of microtubule-stabilizing agents, demonstrate anticancer activity in preclinical models.
- Epothilones possess a distinct tubulin-binding site compared to taxanes, suggesting non-overlapping resistance mechanisms.
Purpose of the Study:
- To evaluate the efficacy and tolerability of epothilones in patients with castration-resistant prostate cancer (CRPC).
- To explore the potential of epothilones as a therapeutic option in CRPC, particularly in patients progressing on taxane-based regimens.
Main Methods:
- Review of early-phase and phase II clinical trials involving ixabepilone, patupilone, and sagopilone in CRPC patients.
- Analysis of treatment outcomes, including objective responses, prostate-specific antigen declines, and adverse events.
- Assessment of epothilone activity as single agents and in combination therapies.
Main Results:
- Ixabepilone demonstrated objective responses and PSA declines in CRPC patients previously treated with docetaxel.
- Clinical activity was observed with ixabepilone in first- and second-line settings, and with patupilone and sagopilone in phase II trials.
- Epothilones were generally well tolerated, with manageable rates of neutropenia and peripheral neuropathy.
Conclusions:
- Epothilones represent a promising therapeutic class for castration-resistant prostate cancer (CRPC).
- The lack of cross-resistance with taxanes suggests potential for sequential therapy.
- Further evaluation in phase III comparative trials is warranted to define the role of epothilones in CRPC management.
More Related Videos
12:13Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
06:44Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:38Mitogens and the Cell Cycle
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
01:15Drugs that Stabilize Microtubules
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistent Cancers